{"id":529528,"date":"2021-02-09T21:46:01","date_gmt":"2021-02-09T21:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=529528"},"modified":"2021-02-09T21:46:01","modified_gmt":"2021-02-09T21:46:01","slug":"dravet-syndrome-epidemiology-forecast-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/dravet-syndrome-epidemiology-forecast-by-delveinsight_529528.html","title":{"rendered":"Dravet Syndrome Epidemiology Forecast by DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1612855481.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Dravet Syndrome Epidemiology Forecast by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1612855481.png\" alt=\"Dravet Syndrome Epidemiology Forecast by DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\"><strong>DelveInsight<\/strong> has launched a new report<strong> &ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dravet-syndrome-epidemiology-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Dravet Syndrome Epidemiology<\/a>&rdquo;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Dravet syndrome (DS) is a rare, catastrophic, lifelong form of epilepsy that begins in the first year of life with frequent and\/or prolonged seizures. As per NORD (National Organization for Rare Disorders), it has been defined as a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request from free sample copy-<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dravet-syndrome-epidemiology-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/dravet-syndrome-epidemiology-forecast <\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &lsquo;Dravet Syndrome Epidemiology Forecast to 2030&rsquo; report delivers an in-depth understanding of the disease, historical and forecasted Dravet Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dravet Syndrome Epidemiology <\/strong><\/p>\n<p style=\"text-align: justify;\">Three stages are usually identified in association with DS with &ldquo;Febrile stage&rdquo; being the first among them, Worsening stage&rdquo; follows between 1 and 5 years of age and &ldquo;Stabilization stage&rdquo; begins by the end of the first decade in which seizures are less frequent<\/p>\n<p style=\"text-align: justify;\">The Signs and Symptoms of the disease involve seizures, ataxia (balance problems), motor impairment, cognitive impairment, behavioral problems, infections, bone problems, and heart rhythm irregularities.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key facts of<\/strong> <strong>Dravet Syndrome Epidemiology <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>As per DelveInsight&rsquo;s estimates, total incident population of Dravet Syndrome in the 7 major markets was 36,301 in 2017<\/li>\n<li>According to the Dravet Syndrome Foundation, Dravet syndrome is a rare, catastrophic, lifelong form of epilepsy that begins in the first year of life with frequent and\/or prolonged seizures. Previously known as Severe Myoclonic Epilepsy of Infancy (SMEI), it affects 1:15,700 individuals, 80% of whom have a mutation in their SCN1A gene.<\/li>\n<li>As per DelveInsight&rsquo;s estimates, the United States accounted for the maximum number of DS patients with 20,731 cases in 2017 followed by Germany with 2,896 cases<\/li>\n<li>DelveInsight estimates suggest that missense mutation was found to have the highest number of incident cases among DS patient population in the US<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dravet Syndrome Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Incident Population of Dravet Syndrome in 7MM [2017-2030]<\/li>\n<li>Mutations (type and class) associated with Dravet Syndrome in 7MM [2017-2030]<\/li>\n<li>Seizure associated cases of Dravet Syndrome in 7MM [2017-2030]<\/li>\n<li>Gender specific Incidence of Dravet Syndrome in 7MM [2017-2030]<\/li>\n<li>Age specific Incidence of Dravet Syndrome in 7MM (2017-2030)<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dravet Syndrome Population<\/strong><\/p>\n<p style=\"text-align: justify;\">According to the paper titled as &ldquo;Mortality in Dravet syndrome: A review&rdquo; published by Shmuely S et al. 2016 nearly ~73% of the patients die before the age of 10 years. Sudden unexpected death in epilepsy (SUDEP) was the leading cause of death (~49%) followed by status epilepticus (~32%).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dravet Syndrome Epidemiology Report Scope<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Dravet Syndrome report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis and treatment patterns<\/li>\n<li>The Dravet Syndrome Epidemiology Report and Model provide an overview of the global trends of Dravet Syndrome in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)<\/li>\n<li>The report provides insight into the historical and forecasted patient pool of Dravet Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan<\/li>\n<li>The report helps to recognize the growth opportunities in the 7MM with respect to the patient population<\/li>\n<li>The report assesses the disease risk and burden and highlights the unmet needs of Dravet Syndrome<\/li>\n<li>The report provides the segmentation of the Dravet Syndrome epidemiology<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request from free sample copy-<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dravet-syndrome-epidemiology-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/dravet-syndrome-epidemiology-forecast <\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of content<\/strong><\/p>\n<p style=\"text-align: justify;\">1 Key Insights<\/p>\n<p style=\"text-align: justify;\">2 Executive Summary of Dravet Syndrome<\/p>\n<p style=\"text-align: justify;\">3 SWOT Analysis for Dravet Syndrome<\/p>\n<p style=\"text-align: justify;\">4 Dravet Syndrome Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5 Dravet Syndrome: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6 Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">7 Country-wise Epidemiology of Dravet Syndrome<\/p>\n<p style=\"text-align: justify;\">8 United States<\/p>\n<p style=\"text-align: justify;\">9 EU-5<\/p>\n<p style=\"text-align: justify;\">10 Germany<\/p>\n<p style=\"text-align: justify;\">11 France<\/p>\n<p style=\"text-align: justify;\">12 Italy<\/p>\n<p style=\"text-align: justify;\">13 Spain<\/p>\n<p style=\"text-align: justify;\">14 United Kingdom<\/p>\n<p style=\"text-align: justify;\">15 Japan<\/p>\n<p style=\"text-align: justify;\">16 Treatment of Dravet Syndrome<\/p>\n<p style=\"text-align: justify;\">17 Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18 Organizations contributing toward Dravet Syndrome<\/p>\n<p style=\"text-align: justify;\">19 KOL&rsquo;s Views: Dravet Syndrome<\/p>\n<p style=\"text-align: justify;\">20 Case Studies<\/p>\n<p style=\"text-align: justify;\">21 Appendix<\/p>\n<p style=\"text-align: justify;\">22 Report Methodology<\/p>\n<p style=\"text-align: justify;\">23 <strong>DelveInsight <\/strong>Capabilities<\/p>\n<p style=\"text-align: justify;\">24 Disclaimer<\/p>\n<p style=\"text-align: justify;\">25 About <strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;Reasons to buy<\/strong><\/p>\n<p style=\"text-align: justify;\">The Dravet Syndrome Epidemiology report will allow the user to &#8211;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Develop business strategies by understanding the trends shaping and driving the global Dravet Syndrome market<\/li>\n<li>Quantify patient populations in the global Dravet Syndrome market to improve product design, pricing, and launch plans<\/li>\n<li>Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Dravet Syndrome therapeutics in each of the markets covered<\/li>\n<li>Understand the magnitude of Dravet Syndrome population by its epidemiology<\/li>\n<li>The Dravet Syndrome Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dravet-syndrome-market\" target=\"_blank\"><strong>Dravet&nbsp;Syndrome Market<\/strong><\/a><\/li>\n<li><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dravet-syndrome-pipeline-insight\" target=\"_blank\"><strong>Dravet&nbsp;Syndrome&nbsp;Pipeline<\/strong><\/a><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=dravet-syndrome-epidemiology-forecast-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=dravet-syndrome-epidemiology-forecast-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight has launched a new report &ldquo;Dravet Syndrome Epidemiology&rdquo; &nbsp; Dravet syndrome (DS) is a rare, catastrophic, lifelong form of epilepsy that begins in the first year of life with frequent and\/or prolonged seizures. As per NORD (National Organization for &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/dravet-syndrome-epidemiology-forecast-by-delveinsight_529528.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,417,406,423],"tags":[],"class_list":["post-529528","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/529528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=529528"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/529528\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=529528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=529528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=529528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}